Pursuing Charlene's Dream

Sattva S. Neelapu, MD, notes that axi-cel is a highly effective therapeutic approach for patients with relapsed/refractory indolent non-Hodgkin lymphoma.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

In line with its safety and efficacy profile, T-DXd preserved quality of life and neurological function in patients with HER2-positive metastatic breast cancer, irrespective of brain metastases.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Additional exploration may help fully realize the impact of combining immunologic approaches with PARP inhibition, says one expert.

Initial therapy with isatuximab plus VRd followed by its addition to Rd maintenance therapy led to significantly improved MRD negativity and PFS in transplant-ineligible multiple myeloma.